TetraLogic Pharmaceuticals Corp (TLOG)

[harmsen]

The recent failure of our MDS clinical trial with birinapant has seriously damaged our ability to raise new financing in the near future. If we are unable to obtain necessary financing, our ability to complete the development and potential commercialization of our product candidates will be compromised and we will need to downsize or wind down our operations through liquidation, bankruptcy or a sale of our company or our assets. We cannot assure you that we will be able to obtain additional financing on terms we deem to be commercially reasonable, if at all or that the third-party financing that we do obtain will be sufficient to cover our operating expenses, debt expenses and other payment obligations. If we fail to obtain the third-party financing we require, we may be unable to continue our operations at the planned levels or at all. We may then have to sell our company or our assets or file for, or be forced to resort to, bankruptcy protection or liquidation.